REGENXBIO (RGNX) Earnings Date & Reports

Key Takeaways

• REGENXBIO reported third quarter 2026 revenue of $9.16 million, down from $29.73 million in the same period a year earlier.
• Net loss narrowed to $40.74 million, compared with a net loss of $61.94 million in Q3 2025.
• Loss per share was $0.62, ahead of analyst consensus, while revenue came in below estimates.
• The company ended the quarter with $251 million in cash, cash equivalents, and marketable securities, funding operations into late 2027.
• Topline results from the pivotal ATMOSPHERE and ASCENT studies in wet age-related macular degeneration (AMD) are expected before the end of 2026.
• For more context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast pages.
• To discover AI-driven trading ideas across the market, explore Trending AI Robots.

Earnings Context and Why It Matters

REGENXBIO is a clinical-stage biotechnology company built around its proprietary adeno-associated virus (AAV) gene therapy delivery platform. As a pre-revenue-phase business, its quarterly results matter less for the top line than for what they reveal about cash runway and the advancement of its late-stage pipeline. Investors are closely tracking the sura-vec program in wet AMD, being developed with AbbVie, and RGX-202 for Duchenne muscular dystrophy (Duchenne). With pivotal data readouts and a planned regulatory filing approaching, this earnings report serves as a checkpoint on whether the company has the financial flexibility to reach potentially transformative milestones.

Reported Results

For the third quarter ended September 30, 2026, REGENXBIO reported total revenue of $9.16 million, a decline from $29.73 million in the prior-year quarter. License and royalty revenue fell to $5.24 million from $23.61 million, while service revenue was $3.92 million versus $6.13 million a year earlier. The net loss narrowed to $40.74 million, or $0.62 per share, compared with a net loss of $61.94 million, or $1.20 per share, in Q3 2025. Loss per share came in ahead of the consensus estimate, while revenue fell short of analyst expectations.

The company finished the quarter with $251 million in cash, cash equivalents, and marketable securities, up from $241 million at the end of 2025. The balance reflects a $100 million milestone payment from AbbVie received in July 2026 and roughly $108 million in net proceeds from an underwritten public offering. It does not include a $39 million payment received in October 2026 under a settlement agreement with Sarepta Therapeutics.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical resource for investors evaluating names like REGENXBIO and the broader biotech sector.

Market Reaction and Investor Sentiment

The stock has faced sustained pressure in 2026, trading lower year to date as investors weighed pipeline risk against the promise of late-stage gene therapy programs. The third quarter update offered a mixed read: a narrower-than-expected loss per share was offset by revenue that trailed estimates. For a clinical-stage company, however, sentiment continues to revolve around catalysts rather than quarterly revenue. Management reiterated that the BLA (Biologics License Application) submission for RGX-202 remains on track for the first quarter of 2027, with potential accelerated approval in the second half of 2027, and that pivotal wet AMD data are expected before year-end. Those milestones are likely to drive near-term positioning more than the reported financial figures.

Forward Outlook and Key Factors to Monitor

The most important near-term event is the topline readout from the ATMOSPHERE and ASCENT pivotal studies of sura-vec in wet AMD, expected in the fourth quarter of 2026. These results, announced jointly with AbbVie, will be a key test of whether a one-time gene therapy can reduce the burden of frequent anti-VEGF injections while maintaining vision outcomes.

Investors should also track the RGX-202 program in Duchenne muscular dystrophy. The company plans to submit a full BLA in the first quarter of 2027 under the accelerated approval pathway, with potential U.S. approval targeted for the second half of 2027. Outside the U.S., the randomized AFFINITY RISE trial is expected to begin in the first half of 2027.

Finally, cash management remains a central theme. The company has guided to a runway extending into the late fourth quarter of 2027, a projection that does not assume additional non-dilutive funding sources. Continued ZOLGENSMA and ITVISMA royalties, potential future milestone payments, and disciplined spending will be important factors as REGENXBIO works to transition from a clinical-stage developer to a commercial organization.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations